Skip to main content
Advertisement
Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial

February 10, 2026

Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial

In a multi-center, randomized controlled trial, Betina Durovni and colleagues assess the acceptability and safety of a short-course tuberculosis preventive therapy taken daily or weekly for different durations by persons recently exposed to tuberculosis.

Image credit: National Institute of Allergy and Infectious Diseases, Unsplash

01/30/2026

Perspective

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

In this Perspective, Giulia Notini and colleagues discuss why the rapid expansion of antibody-drug conjugates, while redefining treatment options in advanced breast cancer, has also resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.

Image credit: National Cancer Institute, Unsplash

Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

02/10/2026

Editorial

Let her shine: Empowering women and closing India’s gender gap in STEM

In recognition of International day of women and girls in STEM, this Editorial by Aparajita Chattopadhyay reflects on the gender gap in STEM in India, outlining socio-cultural and infrastructural factors, recent promising trends, and what is needed to continue these transformations.

Image credit: ThisisEngineering, Unsplash

Let her shine: Empowering women and closing India’s gender gap in STEM

Get new content from PLOS Medicine in your inbox

PLOS Medicine | ISSN: 1549-1676 (online)